Ceftiofur

Drugbox
IUPAC_name = (6"R",7"R")-7- [ [(2"Z")-2-(2-Amino-1,3-thiazol-4-yl)- 2-methoxyiminoacetyl] amino] -3-(furan-2- carbonylsulfanylmethyl)-8-oxo-5-thia-1- azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid

---

CAS_number = 80370-57-6
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
C=19|H=17|N=5|O=7|S=3
molecular_weight = 523.56 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987. [cite journal |author=Yancey RJ, Kinney ML, Roberts BJ, Goodenough KR, Hamel JC, Ford CW |title=Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in mice |journal=Am. J. Vet. Res. |volume=48 |issue=7 |pages=1050–3 |year=1987 |pmid=3631686 |doi=] It is marketed by pharmaceutical company Pfizer as Excede. [cite web |url=http://www.pfizerah.com/index_species.asp?species=DA&country=US&lang=EN |title=Pfizer Animal ealth Dairy Information on Products and Solutions |accessdate=2007-11-20 |format= |work=]

It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against Gram-positive and Gram-negative bacteria. "E. coli" strains resistant to ceftiofur have been reported. [cite journal |author=Donaldson SC, Straley BA, Hegde NV, Sawant AA, DebRoy C, Jayarao BM |title=Molecular epidemiology of ceftiofur-resistant Escherichia coli isolates from dairy calves |journal=Appl. Environ. Microbiol. |volume=72 |issue=6 |pages=3940–8 |year=2006 |pmid=16751500 |doi=10.1128/AEM.02770-05]

References

External links

* [http://www.excede.com/ Official website]